ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 2497 • ACR Convergence 2024

    Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US

    Muhammad Shamim1, Mazen Allouni2, Haseeb Chaudhary3, Ansaam Daoud4, Loai Dweik5, Hashim Syed6 and Omer Pamuk7, 1University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, 2Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, 3Case Western Reserve University, Westlake, OH, 4Case Western Reserve University/University Hospitals, Akron, OH, 5Cleveland Clinic Akron General Internal Medicine, Akron, OH, 6Case Western/ UH, Cleveland, 7University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem.  There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…
  • Abstract Number: 0269 • ACR Convergence 2024

    Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease

    Yiling Zhang1, Sara Tedeschi2, Abhishek Abhishek3, Owen Hensey4, David Grossberg5, Ken Cai6, Beverley Shea7, Jasvinder Singh8, Robin Christensen9, Teodora Serban10, Edoardo Cipolletta11, Konstantinos Parperis12, César Díaz13, Geraldine McCarthy14, Fabio Becce15, Tamer A Gheita16, Silvia Sirotti17, Sara Nysom Christiansen18, Luis Coronel Tarancon19, Lisa Stamp20, Yousra H Abdel-Fattah21, Tristan Pascart22, Georgios Filippou17, Lih En Hong23, John FitzGerald24 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Brigham and Women's Hospital, Boston, MA, 3University of Nottingham, Nottingham, United Kingdom, 4OMERACT patient research partner, Dublin, Ireland, 5OMERACT patient research partner, Maryland, 6Westmead Hospital, Sydney, New South Wales, Australia, 7Ottawa Hospital Research Institute, Ottawa, ON, Canada, 8Baylor College of Medicine, Birmingham, AL, 9Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 10Ospedale La Colletta, Bucharest, Romania, 11Polytechnic University of Marche, Ancona, Italy, 12University of Cyprus Medical School, Nicosia, Cyprus, 13Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 14Mater Misericordiae University Hospital, Dublin, Ireland, 15Lausanne University Hospital (CHUV), Lausanne, Switzerland, 16Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, 17IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, 18Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, 19Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, 20University of Otago, Christchurch, Christchurch, New Zealand, 21Alexandria University, Alexandria, Egypt, 22Lille Catholic University, Lille, France, 23Royal Adelaide Hospital, Unley Park, South Australia, Australia, 24UCLA, Los Angeles, CA

    Background/Purpose: To agree on important domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for long-term studies of calcium pyrophosphate deposition (CPPD) disease.Methods:…
  • Abstract Number: 0542 • ACR Convergence 2024

    Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study

    Clementina López Medina1, Sofia Ramiro2, Dafne Capelusnik3 and Anna Molto4, 1Reina Sofia University Hospital, Cordoba, Spain, 2Leiden University Medical Center, Bunde, Netherlands, 3Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 4Groupe Hospitalier Cochin, AP-HP, Paris, France

    Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…
  • Abstract Number: 0659 • ACR Convergence 2024

    Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

    Richard Furie1, Jorge A. Ross Terres2, Elsa Martins3, Imran Hassan4, Thomas Schindler3, Jay Garg5, William F. Pendergraft III6, Ana Malvar7 and Brad Rovin8, 1Northwell Health, Manhasset, NY, 2Genentech, Inc,, San Francisco, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Inc., Chapel Hill, NC, 7Organización Médica de Investigación, Buenos Aires, Argentina, 8The Ohio State University, Columbus, OH

    Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
  • Abstract Number: 0857 • ACR Convergence 2024

    Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study

    Yurilu Gonzalez Moret1, Diego Lema2 and Fabian Rodriguez Quinonez3, 1Jefferson Einstein Hospital, Philadelphia, PA, 2Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, 3Einstein Medical Center Philadelphia, Philadelphia, PA

    Background/Purpose: Immunosuppressive therapy, including Tumor necrosis factor inhibitors (TNFi), is commonly used in the treatment of various inflammatory conditions, including extracardiac sarcoidosis. However, the use…
  • Abstract Number: 1180 • ACR Convergence 2024

    Relationship Between Changes in Physical Activity and Early Onset Knee Osteoarthritis in Individuals After ACL Reconstruction

    David Werner1, Yvonne Golightly1, Michael Rosenthal1, Balasrinivasa Sajja1, Christopher Wichman1, Melissa Manzer2, Matthew Tao1 and Elizabeth Wellsandt1, 1University of Nebraska Medical Center, Omaha, NE, 2Private Practice, Omaha

    Background/Purpose: Low physical activity levels are associated with osteoarthritis (OA) development and progression in individuals at risk for OA development. Including both structural and symptomatic…
  • Abstract Number: 1527 • ACR Convergence 2024

    Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network

    Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

    Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
  • Abstract Number: 1977 • ACR Convergence 2024

    Three-dimensional Stereophotogrammetry Has Utility in Tracking Upper Eyelid Involvement and Overall Disease Worsening in Patients with Craniofacial Localized Scleroderma

    Tyler Cepica1, Jennifer Foster2, Priya Sarlashkar2, Rami Hallac3 and Heidi Jacobe2, 1University of Texas Southwestern Medical School, Benbrook, TX, 2The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, 3The University of Texas Southwestern Medical Center, Department of Pastic Surgery, Dallas, TX

    Background/Purpose: Craniofacial localized scleroderma’s (LoS) indolent and subtle course poses challenges in quantifying disease progression. Traditional serial photography and the Localized Scleroderma Cutaneous Assessment Tool…
  • Abstract Number: 2246 • ACR Convergence 2024

    Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial

    Veena Ranganath1, Holly Wilhalme2, Nicolette Morris3, Jenny Brook2, Mihaela Taylor1, Howard Yang1, Tanaz Kermani4, Thanda Aung2, Brian Skaggs1, David Elashoff5 and ziva Cooper6, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA, 4University of California Los Angeles, Santa Monica, CA, 5UCLA Department of Medicine Statistics Core, Los Angeles, 6UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles

    Background/Purpose: There is no cure for rheumatoid arthritis (RA) and remission rates vary greatly 10-60%; thus, there is an unmet need for safe adjunctive therapeutic…
  • Abstract Number: 2501 • ACR Convergence 2024

    Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency

    Rohit Vijjhalwar1, Vithushanan Ketheeswaranathan2, Aman More2, Rajinder Andev3 and Shirish Dubey4, 1University of Oxford, Staines, United Kingdom, 2Medical Sciences Division, University of Oxford, Oxford, United Kingdom, 3Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, 4Oxford University Hospitals NHS FT, Oxford, United Kingdom

    Background/Purpose: Non-infectious Aortitis is a rare form of large vessel vasculitis which has a high risk of complications1. There is limited data on the management…
  • Abstract Number: L06 • ACR Convergence 2023

    Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)

    Kathryn Torok1, Paulina Horvei1, Franziska Rosser1, Kirsten Rose-felker2, Vibha Sood2, Adam Olsen2, Nicole Hogue2, Vickie Vandergrift2, Lauren Farver2, Devin Mcguire2, Jonathan Li3, Haley Havrilla2, Jessie Alexander4, Shawna McIntyre2 and Paul Szabolcs1, 1University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4Stanford Children's Hospital, Palo Alto, CA

    Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
  • Abstract Number: L19 • ACR Convergence 2023

    A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks

    George Spencer-Green1, David Hunter2, Thomas Schnitzer3, Sheue-Fang Shih4, Tien-Tzu Tai4, Cathy Kao4 and Siao-Ning Huang4, 1Taiwan Liposome Company, Cambridge, MA, 2Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Taiwan Liposome Company, Taipei, Taiwan (Republic of China)

    Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
  • Abstract Number: 0329 • ACR Convergence 2023

    Factors Associated with Suicidal Ideation Among Patients with Inflammatory Rheumatic Musculoskeletal Disease: A Case-Control Study

    Eike von Schlichting1, Jan Dieris-Hirche2, Imke Redeker3, Xenofon Baraliakos4 and Uta Kiltz5, 1Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, 2LWL-University Hospital, Department of Psychosomatic Medicine and Psychotherapy, Ruhr Universität Bochum, Bochum, Germany, 3Ruhr Universität Bochum, Bochum, Germany, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: Mental health contributes to the morbidity of patients with inflammatory rheumatic musculoskeletal disease (iRMD). Despite extensive research conducted on the prevalence of depressive disorders,…
  • Abstract Number: 0619 • ACR Convergence 2023

    Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review

    liubov Petelytska1, Francesco Bonomi2, Carlo Cannistrà3, elisa Fiorentini4, Silvia Peretti3, Sara Torracchi3, Pamela Bernardini3, Carmela Coccia3, Riccardo De Luca3, Alessio Economou3, Juela Levani5, marco Matucci Cerinic6, Oliver Distler7 and Cosimo Bruni7, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2University of Florence, Firenze, Italy, 3University of Florence, Florence, Italy, 4Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Firenze, Italy, 5Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, 6Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    Background/Purpose: There is no established consensus on defining the clinical course and the outcomes of systemic sclerosis-associated interstitial lung disease (SSc-ILD), both among experts and…
  • Abstract Number: 1140 • ACR Convergence 2023

    Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage Is More Prominent and Patient Distress Is as Prominent as Inflammation in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist

    Theodore Pincus1, Tengfei Li2 and Juan Schmukler1, 1Rush University Medical Center, Chicago, IL, 2Georgetown University, Washington, DC

    Background/Purpose: Patients consult rheumatologists for symptoms which may result from inflammatory activity or reversible problems (INF), joint or other organ damage or irreversible problems (DAM),…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology